
Artiam Bio: Advancing biotech with second-gen CB1 antagonists for serious disorder treatment.
Artiam Bio, founded with the mission to advance biotechnology, focuses on developing second-generation type 1 cannabinoid receptor (CB1) antagonists aimed at treating serious disorders. The company leverages its core expertise in cannabinoid receptor biology to create novel, small molecule drugs that offer safe and effective treatment options. Their market focus is on addressing significant diseases through innovative biotechnological solutions.
Notable affiliated individuals and investors include leading experts in biotechnology and pharmaceutical development, although specific names are not publicly disclosed. Artiam Bio has made key achievements in refining CB1 antagonist technology, positioning itself as a pioneer in this niche field. The overall impact of Artiam Bio lies in its potential to revolutionize treatment paradigms for serious health conditions, contributing significantly to medical advancements and patient care.

Artin Bioscience
artinbio.com

Artizan Biosciences

Artbio
artbio.com

Artisan Bio
artisancells.com

Regenerative Bio
regen-bio.us

Aurion Biotech
aurionbiotech.com

Aibios
aibios.com

Curie.Bio
curie.bio

Biotia
biotia.io

Artielle ImmunoTherapeutics

Artiva Biotherapeutics
artivabio.com

Agentix
agentixcorp.com

Apic Bio

AthemBio
athembio.com

ArrePath
arrepath.com
Companies similar to Artiam Bio include Artin Bioscience, Artizan Biosciences, Artbio and Artisan Bio.
Artiam Bio was founded in 2020.
Artiam Bio's headquarters is located in Morrisville, NC, US.
Artiam Bio's most recent funding round was for $70.7k (USD) in September 2022.
As of Sep 22, 2022, Artiam Bio has raised a total of $70.7k (USD).
Artiam Bio has 1 employee as of Feb 4, 2024.